Molecular Partners AG Sustainability Profile
Molecular Partners AG, a pioneering biotechnology company headquartered in Zurich, Switzerland (CH), is at the forefront of developing innovative therapies for serious diseases. Founded in 2004, the company has made significant strides in the field of protein therapeutics, particularly with its proprietary DARPins (Designed Ankyrin Repeat Proteins) technology, which offers unique advantages in specificity and stability. With a strong focus on oncology and infectious diseases, Molecular Partners has established itself as a key player in the biopharmaceutical industry. The company’s lead product candidates, including MP0310 and MP0420, showcase its commitment to addressing unmet medical needs through cutting-edge science. Recognised for its robust pipeline and strategic partnerships, Molecular Partners AG continues to enhance its market position, driving advancements in targeted therapies that promise to transform patient outcomes.
DitchCarbon Score
How does Molecular Partners AG's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Molecular Partners AG's score of 28 is higher than 53% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Molecular Partners AG's reported carbon emissions
Molecular Partners AG, headquartered in Switzerland (CH), currently does not report any specific carbon emissions data, as indicated by the absence of emissions figures in kg CO2e. Additionally, there are no documented reduction targets or climate pledges available from the company. As a result, it is unclear what specific initiatives or commitments Molecular Partners AG has undertaken regarding carbon emissions reduction or climate action. The company does not appear to inherit any emissions data from a parent organisation, nor does it have any cascading targets from initiatives such as the Science Based Targets initiative (SBTi) or the Carbon Disclosure Project (CDP). In the context of the biotechnology industry, companies are increasingly focusing on sustainability and climate commitments. However, without specific data or commitments from Molecular Partners AG, it is difficult to assess their position or progress in this area.
How Carbon Intensive is Molecular Partners AG's Industry?
How Carbon Intensive is Molecular Partners AG's Location?
Molecular Partners AG's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Molecular Partners AG has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
